Navigation Links
Mentice AB Announces the Appointment of Lars Lonn as Clinical Director for Mentice
Date:3/28/2008

GOTHENBURG, Sweden, March 28 /PRNewswire/ -- Mentice AB, a leading supplier of virtual reality based training applications within the field of medicine has recently appointed Lars Lonn as Clinical Director for Mentice.

Professor Lonn, an Interventional Radiologist, is also a leading European professor within the field of Endovascular Surgery and a faculty member of Rigshospital Health Sciences in Copenhagen, Denmark.

Professor Lonn recently completed a study with Max Berry, MD, Mikael Hellstrom, MD, Jan Gothlin, MD, and Richard Reznick, MD, MEd, FRCSC, which was featured in the Journal of Vascular Interventional Radiology entitled, "Endovascular Training with Animals versus Virtual Reality Systems: An Economic Analysis."

Goran Malmberg, CEO and President of Mentice said, "This is a monumental step forward for us. Professor Lonn will have a vital role with Mentice verifying the direction of our product development, while increasing the awareness and need for training solutions in healthcare. In the long run, we feel that Clinical Directors will play a vital role in driving medical training through the use of medical simulation."

About Mentice:

Mentice is a leader in medical simulation with approximately 600 installations worldwide, 100 validation studies and more than 30 issued and pending patents. Mentice's Family of Procedicus (TM) simulators focus on the area of minimally invasive surgery within the fields of endovascular intervention, core skills training, laparoscopy and arthroscopy training.

Website info: http://www.mentice.com

For more information contact: Goran Malmberg at +46 31 33 99 401 (Gothenburg office) or email, goran.malmberg@mentice.com.

Release #32808


'/>"/>
SOURCE Mentice Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, ... and biotechnology industries to improve patient outcomes and quality of life, will now ... testing are being attributed to new regulatory requirements for all new drug products, ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... ... 2017 , ... Proscia Inc ., a data solutions ... “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, Managing ... how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
Breaking Biology Technology:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... Vehicle Access System Market Analysis & Trends - Industry Forecast to ... ... poised to grow at a CAGR of around 15.1% over the ... This industry report analyzes the market estimates and forecasts for ...
Breaking Biology News(10 mins):